Bayer-Aphea.Bio deal targets next-gen bioinsecticides as ag majors continue biologicals push

Bayer and Aphea.Bio have entered a strategic partnership to co-develop bioinsecticides targeting sap-sucking insects, marking a broader industry shift toward nature-based crop protection. The collaboration combines Aphea.Bio’s microbial metabolite pipeline with Bayer’s global development and commercialization capabilities, initially focusing on fruit crops with plans to expand further. This move reflects the increasing investment by major agricultural companies in biological solutions as key growth drivers, amid regulatory pressures and resistance challenges facing conventional products. Bayer’s diversification into biologicals is further driven by ongoing litigation over glyphosate, though the company maintains that its strategy is focused on performance and innovation rather than a direct response to legal issues.